Agenus to present Phase 1, Phase 2 trial data at ASCO meeting

Agenus announced plans to present clinical data at the American Society of Clinical Oncology 2023 Annual Meeting, to be held June 2-6 in Chicago, IL. Data from a single-arm, open-label Phase 2 study of balstilimab and zalifrelimab plus doxorubicin in patients with advanced sarcomas will be presented at an oral session on Monday, June 5 from 11:30am – 2:30pm CDT. Complete results from the monotherapy arm of the first-in-human dose escalation study of AGEN2373 in patients with advanced solid tumors will be presented at a poster discussion on Saturday, June 3rd from 3:00pm – 4:30pm CDT.